间歇性抗雄激素治疗对前列腺癌和前列腺增生的患者前列腺体积及下尿路症状的影响  

impact of intermittent androgen deprivation therapy on prostate volume and lower urinary tract symptoms in patients with prostate cancer combined with prostatic hyperplasia

作　　者：郝文科[1] 黄柳一[2] 何文娜[1] 刘伟[1] 余枫[1] 吴燕华[1] 钱芸娟[1] 

机构地区：[1]广东省医学科学院广东省人民医院广东省老年医学研究所泌尿内科,广州510080 [2]中山大学附属第一医院泌尿内科

出　　处：《中华老年医学杂志》2013年第8期850-852,共3页Chinese Journal of Geriatrics

摘　　要：目的研究间歇性抗雄激素治疗对前列腺癌和前列腺增生症（BPH）患者的前列腺体积及下尿路症状（LUTS）的影响，并通过与常规药物比较，了解两种治疗方法的有效性。方法对诊断为前列腺癌（57例）及BPH（83例）的患者分别进行抗雄激素和非那雄安联合a受体拮抗剂治疗。并在治疗前、治疗后1、3、6及12个月分别观察患者的前列腺体积、国际前列腺症状评分（IPSS）、生活质量指数（QOL）及最大尿流率（Qmax），比较两种治疗方法对这些指标的影响。结果抗雄激素治疗组前列腺癌患者的前列腺体积，IPSS、QOL评分及Qmax的改善高于接受常规的非那雄安联合a受体拮抗剂治疗的BPH组，差异有统计学意义（均P〈0．05）。结论抗雄激素治疗能明显改善前列腺癌患者的前列腺体积及LUTS，并且效果明显优于非那雄安联合a受体拮抗剂治疗。Objective To explore the impact of intermittent androgen deprivation therapy on prostate volume and lower urinary tract symptoms （LUTS） in patients with prostate cancer combined with prostatic hyperplasia （BPH）, and to evaluate the clinical effect of intermittent androgen deprivation therapy as compared with conventional drug in patients with BPH. Methods Patients with prostate cancer （n=57） and BPH （n=83） were respectively treated with intermittent androgen deprivation therapy and finasteride combined with alpha-receptor antagonist. Prostate volume, international prostate symptom score （IPSS）, quality of life index （QOL） and maximum urinary flow rate （Qmax） in patients were observed before and 1, 3, 6 and 12 months after treatment. Results The improvements in prostate volume, IPSS, QOL and Qmax were higher in prostate cancer patients treated with intermittent androgen deprivation therapy than in BPH patients treated with finasteride combined with alpha-receptor antagonist （P 〈0. 05 ）. Conclusions Intermittent androgen deprivation therapy can significantly reduce prostate volume and improve LUTS in patients with prostate cancer, and has a better clinical effect than finasteride combined with alpha-receptor antagonist treatment.

关 键 词：雄激素拮抗药 前列腺肿瘤 前列腺增生 

分 类 号：R737.25[医药卫生—肿瘤]